IPM chemotherapy in cytokine refractory renal cell cancer

Renal cell carcinoma (RCC) is notoriously chemoresistant. Current management of metastatic disease usually includes immunological agents of which the most clearly evaluated is alpha interferon. Following the failure of such agents no clear second-line therapy exists. The use of a novel combination o...

Descripción completa

Detalles Bibliográficos
Autores principales: Shamash, J, Steele, J P, Wilson, P, Nystrom, M, Ansell, W, Oliver, R T D
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377110/
https://www.ncbi.nlm.nih.gov/pubmed/12771915
http://dx.doi.org/10.1038/sj.bjc.6600934

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377110/
https://www.ncbi.nlm.nih.gov/pubmed/12771915
http://dx.doi.org/10.1038/sj.bjc.6600934

Ejemplares similares